OZEM vs. ARKG ETF Comparison
Comparison of Roundhill GLP-1 & Weight Loss ETF (OZEM) to ARK Genomic Revolution Multi-Sector ETF (ARKG)
OZEM
Roundhill GLP-1 & Weight Loss ETF
OZEM Description
OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
Grade (RS Rating)
Last Trade
$25.91
Average Daily Volume
37,536
14
ARKG
ARK Genomic Revolution Multi-Sector ETF
ARKG Description
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.Grade (RS Rating)
Last Trade
$23.83
Average Daily Volume
2,221,130
34
Performance
| Period | OZEM | ARKG |
|---|---|---|
| 30 Days | -7.33% | 1.19% |
| 60 Days | -7.73% | -6.00% |
| 90 Days | -10.10% | -11.64% |
| 12 Months | -13.66% |
OZEM Underweight 32 Positions Relative to ARKG
| Symbol | Grade | Weight | |
|---|---|---|---|
| TWST | D | -8.37% | |
| RXRX | F | -7.42% | |
| CRSP | D | -7.34% | |
| ADPT | C | -5.03% | |
| CDNA | D | -4.77% | |
| VCYT | B | -4.51% | |
| SDGR | C | -4.14% | |
| BEAM | D | -4.01% | |
| NTLA | F | -3.89% | |
| IONS | F | -3.85% | |
| NTRA | B | -3.82% | |
| NRIX | D | -3.78% | |
| TXG | F | -3.56% | |
| GH | B | -3.49% | |
| ARCT | F | -3.19% | |
| PSNL | D | -2.7% | |
| ABSI | F | -2.19% | |
| PACB | F | -2.16% | |
| BFLY | B | -1.71% | |
| VEEV | C | -1.7% | |
| ACCD | D | -1.47% | |
| VRTX | F | -1.29% | |
| ILMN | D | -1.25% | |
| CERS | C | -1.18% | |
| INCY | C | -1.11% | |
| PRME | F | -0.9% | |
| CMPS | F | -0.75% | |
| MASS | F | -0.69% | |
| QSI | C | -0.68% | |
| EXAS | D | -0.65% | |
| RPTX | F | -0.64% | |
| MRNA | F | -0.01% |
OZEM: Top Represented Industries & Keywords
ARKG: Top Represented Industries & Keywords
Compare ETFs
